RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD)

Historical Holders from Q4 2019 to Q3 2025

Symbol
RLMD on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 par value per share
Shares outstanding
73,819,979
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
7,739,580
Holdings value
$15,541,689
% of all portfolios
0%
Number of holders
43
Number of buys
14
Number of sells
-19
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Ikarian Capital, LLC 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025
Squadron Capital Management LLC 9.9% +61.7% $1,980,090 +$749,475 3,298,500 +60.9% Squadron Capital Management LLC 30 Jun 2025

Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 7,739,580 $15,541,689 +$5,268,375 $2.01 43
2025 Q2 5,303,151 $3,177,608 -$311,761 $0.6003 48
2025 Q1 6,219,491 $1,678,348 -$765,348 $0.27 43
2024 Q4 8,399,225 $4,362,564 -$9,886,723 $0.52 48
2024 Q3 12,376,687 $40,240,571 -$3,630,516 $3.24 69
2024 Q2 13,555,167 $40,671,232 -$3,047,999 $3 78
2024 Q1 14,295,630 $66,487,069 +$3,440,282 $4.65 90
2023 Q4 13,621,440 $56,386,775 -$3,313,848 $4.14 83
2023 Q3 14,992,668 $44,979,292 -$3,168,578 $3 87
2023 Q2 16,099,667 $39,628,526 -$4,052,287 $2.46 91
2023 Q1 17,764,331 $40,142,172 -$4,573,760 $2.26 87
2022 Q4 19,144,470 $66,816,077 -$456,735,123 $3.49 106
2022 Q3 25,783,847 $954,470,507 +$46,796,895 $37.02 131
2022 Q2 24,632,853 $467,785,642 +$33,496,825 $18.99 106
2022 Q1 23,069,358 $622,305,579 +$69,498,228 $26.99 107
2021 Q4 20,739,885 $467,189,248 +$239,138,409 $22.53 91
2021 Q3 10,023,314 $262,675,920 -$4,620,967 $26.21 81
2021 Q2 9,944,006 $318,306,821 +$11,580,961 $32.01 83
2021 Q1 9,536,264 $335,739,251 +$3,534,612 $35.21 81
2020 Q4 9,311,019 $298,677,225 -$48,362,964 $32.07 79
2020 Q3 10,443,239 $392,874,164 -$4,538,306 $37.62 72
2020 Q2 10,506,228 $469,323,200 +$57,833,259 $44.75 74
2020 Q1 9,357,083 $319,169,853 +$94,707,648 $34.11 43
2019 Q4 6,797,480 $265,100,975 +$264,710,973 $39 44